How has Replimune Group's software and technology licenses, net changed year-over-year?

Replimune Group's software and technology licenses, net decreased by 0.0% year-over-year, from $1.2M to $1.2M.

Replimune Group REPL Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

Inhibrx Biosciences, Inc.INBX

——

ImmunomeIMNM

——

CG OncologyCGON

——

Erasca, Inc.ERAS

——

Other financials

Income statement

See full

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

See full

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

See full

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation

See full

Market cap$930.59M+28.6%

Enterprise value$885.15M+28.3%

Returns & leverage

See full

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Replimune Group's software and technology licenses, net?: Replimune Group (REPL) reported software and technology licenses, net of $1.2M in Q4 2025.
How has Replimune Group's software and technology licenses, net changed year-over-year?: Replimune Group's software and technology licenses, net decreased by 0.0% year-over-year, from $1.2M to $1.2M.